Rheumatoid Arthritis Treatment Market Insights - A Deep Dive Study Of Causes and Future of Treatments
Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects about 1% of the world's population. It causes inflammation in the joints and other surrounding tissues in the body. Some of the common symptoms include joint pain, stiffness, swelling, limited range of motion, fatigue, fever, and loss of appetite. The exact cause of RA is unknown, but it is thought to be a combination of genetic and environmental factors. There is no cure for RA, but treatment options include medication, physical therapy, and surgery.
RA is more common in women than in men, and the risk increases with age. The prevalence of RA varies between different regions and populations. The prevalence of RA is estimated to be increasing globally, due to factors such as an aging population, improved diagnosis, and a better understanding of the disease. It's also important to note that RA can have a significant impact on the quality of life of those affected, and it also has economic implications, such as increased healthcare costs and loss of productivity.
RA often goes undiagnosed or misdiagnosed in its early stages, and early diagnosis is crucial for preventing or slowing the progression of joint damage and improving the quality of life of those affected. Hence, RA awareness is important for early diagnosis, providing support to those affected, encouraging people to seek treatment, and promoting research to improve understanding of the condition and develop better treatments.
The increasing prevalence of RA, advancements in technology, the aging population, increasing healthcare expenditure, and high unmet needs are some of the key drivers of this market. In addition, there are several government initiatives such as the National Rheumatoid Arthritis Society (NRAS), and European League Against Rheumatism (EULAR) aimed at increasing awareness about rheumatoid arthritis (RA) and promoting early diagnosis and treatment.
Medications are an integral part of the treatment of RA including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologics, Janus kinase (JAK) inhibitors, analgesics, and corticosteroids. The current trend in the treatment of RA is to use a combination of medications to achieve and maintain remission. Nowadays, Biologic drugs such as tumor necrosis factor (TNF) inhibitors, peptide-based therapies, and cell-based therapies are becoming increasingly popular due to their effectiveness in reducing inflammation and slowing the progression of joint damage. Additionally, there is a growing focus on precision medicine and the use of genetic markers to predict which patients will respond best to certain treatments.
North America accounted for more than 40% of the rheumatoid arthritis therapeutics market. Heightened awareness of disease remittance therapies among patients, rising prevalence of RA, and high public and private healthcare spending are stimulating the growth of the region. Moreover, easy access to quality healthcare, favorable reimbursement policies, a strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America. Asia Pacific is likely to post the highest CAGR owing to the growing adoption of urban lifestyle is leading to expanding base of patients in the region coupled with increasing healthcare spending.
Rheumatoid Arthritis (RA) market is highly competitive and composed of various players, including pharmaceutical companies, biotechnology companies, and medical device manufacturers. Some of the major players include AbbVie, Amgen, Bristol-Myers Squibb, Pfizer, Roche, Janssen Biotech, Eli Lilly and Company, AstraZeneca, Merck, and GlaxoSmithKline. Companies are implementing various strategies such as developing new drugs, partnerships, acquisitions, promoting their brand, and providing cost-effective solutions. Also, Companies focus on developing drugs that are tailored to the specific needs of individual patients, by using predictive biomarkers, genetic and genomic information, and other precision medicine strategies. For instance, in February 2022, Xbrane Biopharma AB and Biogen Inc. signed a commercialization and license agreement to develop, manufacture, and launch Xcimzane, a preclinical monoclonal antibody that is suggested biosimilar of CIMZIA for the treatment of RA.
Check out reports related to Arthritis Treatment and Therapeutics, published by Grand View Research